Theragent Embraces Pharma 4.0 with AI Software Provider, Insight68
Theragent, a cell therapy CDMO focused on advancing next-generation cancer and rare disease treatments, has signed a multi-year exclusive contract with Insight68, an AI-driven software provider that aims to digitalize and streamline the cell therapy manufacturing process. This partnership reinforces Theragent’s commitment to 100% digital batch record compliance and elevates the company’s reputation as a […]
Read More
Theragent Secures Novel Stem Cell Bank Production Contract with Accelerated Biosciences
Theragent has announced an agreement with Accelerated Biosciences, a regenerative medicine innovator, to produce the cGMP-grade master cell bank (MCB) for Accelerated Biosciences’ novel human Trophoblast Stem Cells (hTSCs). Accelerated Biosciences’ hTSCs are pluripotent and immune-privileged stem cells that are derived from an ethical source and can be differentiated into a number of cell therapies. […]
Read More
CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy
Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, has announced that they have been selected by CellVax Therapeutics to provide manufacturing and testing services for CellVax’s novel cancer immunotherapy candidate FK-PC101 entering Phase 2 clinical trials. FK-PC101 is a cell-based autologous cancer vaccine for […]
Read More